I. Skin Cancers

a. Epidemiologic/Correlative

UCI 18-05
Molecular epidemiology on gender difference in melanoma risk (Liu-Smith)

UCI 09-17
Biology of Human Melanocytes and Keratinocytes (Meyskens)

UCI 14-25
Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

UCI 16-01
(PAINT)-Pathway Analyses for Individualized Network Therapeutics for Cancer (Nelson)

UCI 15-40
Prospective and Retrospective Study of Outcomes for Patients with Malignant Melanoma (Yamamoto)

b. Screening/Diagnostic

UCI 11-30
Skin imaging with Technologies in Development (Kelly)

UCI 13-13
Pilot study on in-vivo non-invasive skin imaging using multiphoton microscopy and multispectral imaging (Kelly)

UCI 15-08
Spectral comparison between Spatially Modulated Quantitative Spectroscopy (SMoQS) and Polarization Sensitive Hyperspectral Multimode Dermoscopy for the purpose of skin compositional analysis (Kelly)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**Opening soon**

Version 10/18
II. Cutaneous Melanoma

a. Screening/Diagnostic

UCI 16-82  DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study #4 (Yamamoto)

UCI 14-05  Multi-Center Evaluation of Oncogenesis via Spectral Analysis with the Melanoma Advanced Imaging Dermascope (mAID) (Linden/Kelly)

b. Metastatic: Unresectable Not Previously Treated

i. BRAF Mutated Only

UCI 17-73  A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors (Fruehauf)

ii. BRAF Wild-Type Only

UCI 16-102-Suspended- A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced BRAFV600 Wild-Type Melanoma (Fruehauf)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu
III. Cutaneous T-Cell Lymphoma (CTCL)

a. Screening/Diagnostic

UCI 16-37**Pending
Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome (Pinter-Brown)

UCI 16-46
A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects with Various Lymphomas and Leukemias (Pinter-Brown)

UCI 17-36
A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma (Pinter-Brown)

UCI 17-82
A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-Cell Lymphoma (CTCL), stages IA, IB and IIA (Pinter-Brown)

b. Therapeutic

IV. Miscellaneous & Phase 1 Clinical Trials

ECOG-EAY131
Molecular Analysis for Therapy Choice (MATCH) (Bota)

UCI 16-96
A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Zhu)

UCI 18-19
Ph Ib Study of IBI308 (PD-1 antagonist) for Advanced/ Metastatic Solid Malignancies (Zhu)

UCI 18-14
Ph I Trial of RMC-4630 (PTP SHP2’) Monotherapy for Relapsed/ Refractory Solid Tumors (Ou)

SWOG S1609 (CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

UCI 18-21**Pending
Ph I/II LOXO-292 for RET Fusion+ Solid Tumors, Medullary Thyroid Ca & Other Tumors w/RET Activation (Ou)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**Opening soon